SHR-1701 + gemcitabine + nab-paclitaxel

A three-drug combination therapy consisting of **SHR-1701** (a bifunctional fusion protein composed of a monoclonal antibody against programmed death ligand 1 fused with the extracellular domain of TGF-β receptor II), **gemcitabine** (a nucleoside analog and anti-metabolite chemotherapeutic), and **nab-paclitaxel** (an albumin-bound formulation of the mitotic inhibitor paclitaxel). SHR-1701 blocks the immunosuppressive PD-L1 pathway and sequesters TGF-β, thereby enhancing anti-tumor immune responses and counteracting the pro-tumorigenic effects of TGF-β; it is being investigated in advanced solid tumors and several cancer types[1][3][5][7]. Gemcitabine interferes with DNA synthesis, while nab-paclitaxel stabilizes microtubules, leading to apoptosis of cancer cells. The combination of gemcitabine with nab-paclitaxel is well established in metastatic pancreatic cancer and being investigated in other solid tumors[2][4][6]. The triple combination aims to leverage chemotherapy-induced tumor reduction with enhanced immunotherapy for potentially synergistic anti-cancer effects.

Other names

albumin-bound paclitaxel